NanoViricides CEO publishes letter to shareholders
NanoViricides has published a letter from its CEO addressing its shareholders on its website. CEO Eugene Seymour describes the progress that the company has made towards entering human clinical trials. The company believes that a nanoviricide skin cream against shingles will be its first drug to go into human clinical studies. The company expects that additional HerpeCiode program topical drug candidates will follow the shingles drug candidate into the clinic. The letter also lays out the steps to advance the shingles drug into human trials. The company has four different drugs in development in the HerpeCide program. All of these high priority drugs are expected to enable a relatively rapid regulatory process as compared to systemic drugs. The company also has four more systemically delivered drugs in different preclinical development stages that are expected to mature towards the clinic. The company continues to work on these drug candidates at lower priorities, due to resource limitations. The company believes it now has the infrastructure to develop antiviral drugs from discovery all the way to clinical product manufacture in its new campus in Shelton, CT.